Organon Aims to Ignite Worldwide Conversation Around Unplanned Pregnancy
21.9.2021 07:01:00 EEST | Business Wire | Press release
Organon (NYSE: OGN), a global women’s health company, is launching a Public Service Announcement (PSA) that aims to raise awareness and ignite a worldwide conversation about the staggering rates of unplanned pregnancy around the world.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210920005986/en/
Worldwide, unplanned pregnancy impacts approximately 121 million women each year.1 A 2019 study reported that globally, more than 1 billion women have a need for family planning, but for 270 million of them, the need for modern methods of family planning is unmet.2** Unplanned pregnancy can impact any woman anywhere, regardless of her social or economic background.
“While we have seen a lot of progress in the area of reproductive health, the rates of unplanned pregnancy around the world continue to be high,” said Dr. Sandy Milligan, M.D., J.D., head of Organon research and development. “There is no better time than ahead of World Contraception Day to focus on empowering women through education, information, empathy and conversation to help reduce unplanned pregnancy.”
Organon invites women, their families, healthcare professionals and policy makers to visit https://hereforherhealth.com/unplanned/ to share their perspectives on how to help reduce the rates of unplanned pregnancy and join us on a collective mission of having the conversation.
“Now, more than ever, it is critical to focus on the reproductive well-being of all people,” said Dr. Raegan McDonald-Mosley, MD, CEO of Power to Decide. “On World Contraception Day, we have a unique opportunity to highlight the importance of ensuring all people - regardless of who they are, where they live, or their economic background - have the opportunity to decide if, when and under what circumstances to get pregnant or have a child.”
The PSA will air on local TV and radio markets throughout the U.S., be distributed on social media via a variety of global channels and partners, and is available on https://hereforherhealth.com/unplanned/ where people are encouraged to share their perspectives on how to help reduce unplanned pregnancy.
About Organon
Organon is a global healthcare company formed through a spin-off from Merck, known as MSD outside of the United States and Canada, focused on improving the health of women throughout their lives. Here for her health, the company has a portfolio of more than 60 medicines and products across a range of therapeutic areas. Led by the reproductive health portfolio coupled with an expanding biosimilars business and stable franchise of established medicines, Organon’s products produce strong cash flows that will support investments in future growth opportunities in women’s health, including business development like recently acquired Alydia Health, a medical device company focused on postpartum hemorrhage. In addition, Organon is pursuing opportunities to collaborate with biopharmaceutical innovators looking to commercialize their products by leveraging its scale and presence in fast growing international markets.
Organon has a global footprint with significant scale and geographic reach, world-class commercial capabilities, and approximately 9,000 employees with headquarters located in Jersey City, New Jersey.
For more information, visit https://www.organon.com/ and connect with us on LinkedIn and Instagram.
Forward-Looking Statement of Organon
Except for historical information herein, this news release includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, including, but not limited to, statements about management’s expectations about Organon’s future prospects. Forward-looking statements may be identified by words such as “aims,” “potential,” “expects,” “intends,” “anticipates,” “plans,” “believes,” “seeks,” “estimates,” “will” or words of similar meaning. These statements are based upon the current beliefs and expectations of Organon’s management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.
Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of the ongoing COVID-19 pandemic and emergence of variant strains; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; Organon’s ability to accurately predict its future financial results and performance; Organon’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of Organon’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.
Organon does not undertake any obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in Organon’s filings with the Securities and Exchange Commission (“SEC”), including its registration statement on Form 10, available at the SEC’s Internet site (www.sec.gov).
1 Bearak J, Painchalk A, Ganatra B, et al. Unintended pregnancy and abortion by income, region, and the legal status of abortion: estimates from a comprehensive model for 1990–2019. Lancet Glob Health. 2020;8(9):e1152-e1161. doi:10.1016/S2214-109X(20)30315-6
2 Kantorová V, Wheldon MC, Ueffing P, Dasgupta ANZ (2020) Estimating progress towards meeting women’s contraceptive needs in 185 countries: A Bayesian hierarchical modelling study. PLoS Med 17(2): e1003026. https://doi.org/10.1371/journal.pmed.1003026
**According to Kantorová et. al, modern methods of contraception include female and male sterilization, the intrauterine device (IUD), the implant, injectables, oral contraceptive pills, male and female condoms, vaginal barrier methods, the lactational amenorrhea method (LAM), emergency contraception and other modern methods such as the contraceptive patch or vaginal ring.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210920005986/en/
Contact information
Media Contacts:
Karissa Peer
(614) 314-8094
Kate Vossen
(732) 675-8448
Investor Contacts:
Jennifer Halchak
(201) 275-2711
Edward Barger
(267) 614-4669
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
New TOURISE Report Reveals How Traveler Expectations Are Changing the Rules for Global Tourism18.11.2026 14:00:00 EET | Press release
Changing traveler priorities are reshaping global tourism, influencing where people go, how they spend and what they value most from their journeys. A new report released by TOURISE, The Future Traveller, explores these shifts and what they mean for the industry through 2030. Developed in collaboration with Euromonitor International, the report draws on consumer surveys and perspectives from industry leaders. The report finds that travel decisions are increasingly shaped by the priorities and circumstances of each trip, rather than demographics alone. It calls on destinations and businesses to rethink how they attract visitors and measure success, shifting the focus from high-spending travelers to high-value trips that deliver meaningful experiences, support local economies and create lasting benefits for communities. “Travelers are not making decisions as fixed demographic segments. They are responding to purpose, pressures and possibilities of each trip,” said His Excellency Ahmed Al
Grand Prix ACF AutoTech 2027: Applications Open for the 10th Edition18.11.2026 14:00:00 EET | Press release
The Automobile Club de France (ACF) and ESSEC Alumni are launching the 10th edition of the Grand Prix ACF AutoTech, the leading competition for automotive and mobility startups. French and international startups can apply until November 27, 2026 at 11:59 p.m. (CET) at www.grandprixacfautotech.com. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261118772168/en/ Jury members and former finalist startups for the launch of 10th Edition of Grand Prix ACF AutoTech (c) Quentin Vaquez Since 2018, the competition has selected 52 finalists, including Chargemap, Hiflow, ChargeGuru and Geolith, who have together raised more than €700 million. Only 6 have failed: a survival rate of nearly 90%. The 2026 edition rewarded Altrove (Grand Prix ACF), Bloomineral (ACF Pioneer Prize and GreenTech Mention) and IoT.bzh (Industrialization Prize). “Ten editions is an achievement we are proud of. The number of applications, rising every year, shows h
Rockwell Automation Signs Definitive Agreement to Acquire AGILOX18.11.2026 14:00:00 EET | Press release
Rockwell Automation, Inc. (NYSE: ROK), the world’s largest company dedicated to industrial automation and digital transformation, today announced it has signed a definitive agreement to acquire Austria-based AGILOX, a maker of high-end autonomous mobile robots (AMRs) that are driven by self-developed artificial intelligence and swarm networking technology. Together, AGILOX’s proven forklift AMR portfolio and OTTO by Rockwell Automation’s flatbed AMR platform will create a comprehensive autonomous material movement offering, elevating AGILOX from a best-in-class point solution to a cornerstone of a world-class comprehensive production logistics capability. The acquisition will combine OTTO's strong presence in North America with AGILOX's established footprint across Europe. AGILOX will gain access to Rockwell's deep customer relationships in strategic verticals like consumer packaged goods and life sciences. The acquisition will create a stronger partner ecosystem and more than double R
Ant International Pioneers PayNow Deep-Linking for E-Commerce, Explores Government Services Use Case Under MAS’ PayNow Gen2 Initiative18.11.2026 13:40:00 EET | Press release
Ant International is the first partner under the Monetary Authority of Singapore (MAS)’s PayNow Generation 2.0 launch to introduce live use cases for deep-linking for e-commerce and digital government services. The launch is enabled by Antom, its global merchant payment and digitisation services provider, and Antom’s Southeast Asia subsidiary, 2C2P by Antom. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261118384895/en/ At the Singapore Fintech Festival 2026, MAS announced phase 2 of the PayNow Gen2 report, a joint study by the Association of Banks in Singapore (ABS) and the MAS to define the next wave of innovation for Singapore's instant payments system. “PayNow Gen2 marks another important step in Singapore’s journey towards a more innovative, connected and future-ready payments ecosystem," said Gary Liu, Chief Executive Officer of Antom and Senior Vice President of Ant International. “At Ant International, we believe th
IFF Opens Its First Forest Lab in Brazil's Atlantic Forest to Advance Fragrance and Beauty Innovation18.11.2026 13:30:00 EET | Press release
IFF (NYSE: IFF) — a global leader in flavors, fragrances and health and biosciences — today opened its first Forest Lab at Legado das Águas, Brazil's largest private Atlantic Forest reserve. The lab is the next step in the bioprospecting partnership IFF announced in August 2025 with Reservas Votorantim (rV), the green economy division of Brazilian investment firm Votorantim SA, which manages the reserve. Spanning 31,000 hectares and home to nearly 1,000 plant species, Legado das Águas now hosts biodiversity research, scent discovery, perfumery and beauty innovation in one place, while supporting rV's conservation work. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261117495933/en/ A scientist in the new IFF Brazil Forest Lab at Legado das Águas, the country’s largest private Atlantic Forest reserve. “The IFF Brazil Forest Lab brings perfumers, scientists and fragrance and beauty brands directly to the source,” said Ana Paul
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
